Phathom Pharmaceuticals Stock Analysis
| PHAT Stock | USD 5.99 0.35 5.52% |
Phathom Pharmaceuticals is overvalued with Real Value of 5.75 and Hype Value of 5.99. The main objective of Phathom Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Phathom Pharmaceuticals is worth, separate from its market price. There are two main types of Phathom Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Phathom Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Phathom Pharmaceuticals is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day. Phathom Stock trading window is adjusted to America/New York timezone.
Phathom |
Phathom Stock Analysis Notes
About 92.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 5.74. Phathom Pharmaceuticals had not issued any dividends in recent years. Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey. Phathom Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 77 people. To find out more about Phathom Pharmaceuticals contact Terrie Curran at 877 742 8466 or learn more at https://www.phathompharma.com.Phathom Pharmaceuticals Investment Alerts
| Phathom Pharmaceuticals generated a negative expected return over the last 90 days | |
| Phathom Pharmaceuticals has high historical volatility and very poor performance | |
| Phathom Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 682 K. Net Loss for the year was (201.59 M) with profit before overhead, payroll, taxes, and interest of 21.95 M. | |
| Phathom Pharmaceuticals currently holds about 207.39 M in cash with (137.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.39. | |
| Over 92.0% of the company shares are owned by institutional investors |
Phathom Pharmaceuticals Upcoming and Recent Events
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Phathom Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 433.51 M.Technical Drivers
As of the 1st of February, Phathom Pharmaceuticals holds the Variance of 34.38, risk adjusted performance of (0.23), and Coefficient Of Variation of (348.74). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Phathom Pharmaceuticals, as well as the relationship between them.Phathom Pharmaceuticals Price Movement Analysis
The output start index for this execution was thirty-five with a total number of output elements of twenty-six. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Phathom Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Phathom Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Phathom Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Phathom Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Phathom Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Phathom Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Phathom Pharmaceuticals Outstanding Bonds
Phathom Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Phathom Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Phathom bonds can be classified according to their maturity, which is the date when Phathom Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| US717265AM45 Corp BondUS717265AM45 | View | |
| FCX 7125 01 NOV 27 Corp BondUS717265AJ16 | View | |
| US717265AL61 Corp BondUS717265AL61 | View |
Phathom Pharmaceuticals Predictive Daily Indicators
Phathom Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Phathom Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Phathom Pharmaceuticals Forecast Models
Phathom Pharmaceuticals' time-series forecasting models are one of many Phathom Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Phathom Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Phathom Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Phathom Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Phathom shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Phathom Pharmaceuticals. By using and applying Phathom Stock analysis, traders can create a robust methodology for identifying Phathom entry and exit points for their positions.
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey. Phathom Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 77 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Phathom Pharmaceuticals to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Price Ceiling Movement Now
Price Ceiling MovementCalculate and plot Price Ceiling Movement for different equity instruments |
| All Next | Launch Module |
Additional Tools for Phathom Stock Analysis
When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.